The CDC have recognized Enterobacteriaceae as an urgent threat causing up to 140,000 health care associated infections each year in the United States. There is a lack of data assessing the efficacy of different beta-lactam antibiotics for treatment of Enterobacter spp., Serratia marcescens, Citrobacter freundii, Providencia spp., and Morganella morganii (ESCPM) infections. These pathogens contain chromosomally located, inducible AmpC beta-lactamases, a unique mechanism of resistance. Limited data suggest that exposure to third-generation cephalosporins selects for AmpCoverproducing mutants and therefore are not recommended to treat ESCPM infections. Optimal therapy, beyond potentially avoiding third-generation cephalosporins, is unknown.
 The carbapenem group had numerically lower rates of clinical failure, mortality, and readmission. Results were not statistically significant.  Patients in the ICU subgroup had higher rates of clinical failure when treated with cefepime or piperacillin/tazobactam (OR 4.2 95% CI 1.0-18.9) as compared to patients treated with a carbapenem. Other subgroups favored carbapenems but were not statistically significant.  A study with a larger sample size would be needed to determine if the trend is significant in the overall patient population. 
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